Metformin and Severe Post‐COVID‐19 Outcomes Among Individuals With Diabetes Mellitus

Zachary B. Dozier, Lin‐Chiun Wang, Yunwen Ji, A. Jerrod Anzalone, Oluwasolape Olawore, Ryan Hafen, Eric Hurwitz, Manav Kumar, Rena C. Patel, Ariana Budhihartanto, Mark van der Laan, John M. Colford Jr., Alan E. Hubbard, John B. Buse, Steven G. Johnson, Jane Reusch, Lauren E. Chan, Richard Moffitt, Rachel Wong, Carolyn Bramante, on behalf of the National Clinical Cohort Collaborative (N3C) Consortium, Adam B. Wilcox, Adam M. Lee, Alexis Graves, Jerrod) Anzalone, Amin Manna, Amit Saha, Amy Olex,
Diabetes, Obesity and Metabolism · Wiley · 2026-11-06 · DOI: 10.1111/dom.71502

Аннотация

ABSTRACT Aims We evaluated the relationship between metformin, one of the most commonly prescribed medications for individuals with diabetes, and COVID‐19 sequelae. Materials and Methods We evaluated a retrospective cohort of individuals in the National Clinical Cohort Collaborative with Type 2 diabetes mellitus and COVID‐19 who were prescribed metformin or a dipeptidyl peptidase‐4 inhibitor (DPP4i) at least 30 days before the onset of acute COVID‐19 between 1 October 2021, and 15 November 2023. We compared the 12‐month cumulative incidence of Long COVID diagnosis (ICD‐10 U09.9: Post COVID‐19 condition, unspecified), probable Long COVID (based on a model‐derived phenotype), and mortality between individuals prescribed metformin versus DPP4i. We applied Super Learner and targeted maximum likelihood estimation to obtain risk ratios while adjusting for covariates of interest. Results In our sample of 53 332 individuals with Type 2 diabetes and COVID‐19, we found that metformin prescription was associated with a lower risk of all‐cause mortality after COVID‐19 (adjusted risk ratio [aRR]: 0.61, 95% CI: 0.51, 0.73). We also observed that metformin users, compared to DPP4i users, had a slightly lower risk of probable Long COVID (aRR: 0.87, 95% CI: 0.81, 0.94) but did not detect a significant relationship with the clinically defined outcome of Long COVID diagnosis (aRR: 0.90, 95% CI: 0.68, 1.20). Conclusions These findings support the hypothesis that metformin prescription during acute COVID‐19 may be associated with lower mortality among adults with diabetes.

Читать у издателя →

Похожие статьи